reported that human NRAS-mutant NSCLC cells display moderate sensitivity to PAN-RAF inhibitors, and dual-targeted inhibition of PLK1 and PAN-RAF using Volasertib in combination with LXH254 is more effective in inhibiting long-term cell survival compared to LXH254 alone. The gene discussed is RAF1; the disease is non-small cell lung carcinoma.